Active substance
Acebutolol
- US FDA 4
- Health Canada 6
- US price lines 2
- NHS prices 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ACEBUTOLOL HYDROCHLORIDE | EQ 200MG BASE; EQ 400MG BASE | capsule · oral | ANI PHARMS | Prescription | 18 Oct 1995 |
| ACEBUTOLOL HYDROCHLORIDE | EQ 200MG BASE; EQ 400MG BASE | capsule · oral | AMNEAL PHARM | Prescription | 30 Dec 1999 |
| SECTRAL | EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | PROMIUS PHARMA | Discontinued | 28 Dec 1984 |
| ACEBUTOLOL HYDROCHLORIDE | EQ 200MG BASE; EQ 400MG BASE | capsule · oral | PHARMOBEDIENT | Discontinued | 24 Apr 1995 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-ACEBUTOLOL | 02147602 | 100 MG | TABLET · ORAL | APOTEX INC |
| APO-ACEBUTOLOL | 02147610 | 200 MG | TABLET · ORAL | APOTEX INC |
| APO-ACEBUTOLOL | 02147629 | 400 MG | TABLET · ORAL | APOTEX INC |
| TEVA-ACEBUTOLOL | 02204517 | 100 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-ACEBUTOLOL | 02204525 | 200 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-ACEBUTOLOL | 02204533 | 400 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ACEBUTOLOL 200 MG CAPSULE | $0.61477 | per EA | 23 Sep 2026 |
| US NADAC | ACEBUTOLOL 400 MG CAPSULE | $0.84101 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Acebutolol 400mg tablets | £18.62 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.